TSHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Taysha Gene Therapies Inc (TSHA) does not present a compelling buy opportunity for a beginner investor with a long-term focus at this time. While the technical indicators show bullish momentum, the lack of recent news, financial performance data, and weak immediate growth catalysts suggest a cautious approach. Additionally, insider selling and no strong trading signals further support a hold recommendation.
The stock shows bullish momentum with a positively expanding MACD histogram (0.0854), RSI at 76.573 in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 6.356, R2: 6.666), suggesting limited upside in the short term.
Hedge funds are significantly increasing their positions, with buying up by 649.63% over the last quarter. Analysts have raised the price target to $17, citing upcoming trial updates and potential milestones in 2Q26.
Insiders are selling heavily, with a 11823.54% increase in selling activity over the last month. No recent news or congress trading data is available, and the stock has a 70% chance of a slight decline (-1.3%) in the next day.
No financial performance data is available for analysis.
Canaccord analyst Whitney Ijem maintains a Buy rating and has raised the price target from $14 to $17, citing positive trial progress and upcoming data releases.
